Eli Lilly (LLY) Capital Expenditures Growth (1y) (2010 - 2026)
Eli Lilly (LLY) Capital Expenditures Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Capex Growth (1y) (Qtr) |
| 1 |
Gsk |
92,316,836.42 Bn |
92,316,831.46 Bn |
7.76 Bn |
-13.73% |
| 2 |
Eli Lilly |
983.57 Bn |
978.29 Bn |
16.22 Bn |
54.04% |
| 3 |
Johnson & Johnson |
553.56 Bn |
531.50 Bn |
15.96 Bn |
31.95% |
| 4 |
AbbVie |
383.35 Bn |
374.00 Bn |
10.78 Bn |
12.77% |
| 5 |
Merck |
281.71 Bn |
276.06 Bn |
12.09 Bn |
-25.38% |
| 6 |
Amgen |
182.20 Bn |
170.16 Bn |
5.87 Bn |
73.24% |
| 7 |
Gilead Sciences |
153.71 Bn |
145.98 Bn |
5.52 Bn |
12.50% |
| 8 |
Pfizer |
143.75 Bn |
130.98 Bn |
-1.21 Bn |
-22.70% |
| 9 |
Bristol Myers Squibb |
109.71 Bn |
99.25 Bn |
8.07 Bn |
33.46% |
| 10 |
Novartis Ag |
108.28 Bn |
107.60 Bn |
- |
-36.22% |
| Date | Value |
|---|
| Mar 31, 2026 |
54.04% |
| Dec 31, 2025 |
70.21% |
| Sep 30, 2025 |
54.56% |
| Jun 30, 2025 |
38.52% |
| Mar 31, 2025 |
53.10% |
| Dec 31, 2024 |
39.70% |
| Sep 30, 2024 |
39.20% |
| Jun 30, 2024 |
65.92% |
| Mar 31, 2024 |
47.54% |
| Dec 31, 2023 |
113.90% |
| Sep 30, 2023 |
57.21% |
| Jun 30, 2023 |
98.98% |
| Mar 31, 2023 |
82.95% |
| Dec 31, 2022 |
71.83% |
| Sep 30, 2022 |
83.25% |
| Jun 30, 2022 |
-2.70% |
| Mar 31, 2022 |
21.68% |
| Dec 31, 2021 |
-35.91% |
| Sep 30, 2021 |
-14.32% |
| Jun 30, 2021 |
35.31% |
